Background Vitiligo is a chronic skin disorder characterised by patchy loss of skin colour.
Some people experience itching before the appearance of a new patch. It affects people of …

Introduction: Vitiligo is a relatively common autoimmune depigmenting disorder of the skin.
There has been a great advance in understanding the pathological basis, which has led to …

British Association of Dermatologists guidelines for the management of people with vitiligo 2021*
| British Journal of Dermatology | Oxford Academic Skip to Main Content Advertisement intended …

Vitiligo affects around 1% of the world's population. Despite it being relatively common, there
is still no effective treatment. The objective of this study was to update the Cochrane …

Topical corticosteroids (TCs) are the pillars of dermatotherapeutics. These drugs are the
“magic molecules,” provided they are used judiciously and appropriately, following a rational …

Survival analysis is concerned with “time to event” data. Conventionally, it dealt with cancer
death as the event in question, but it can handle any event occurring over a time frame, and …

There is currently no definitive treatment for vitiligo; various modalities include immune
modulators phototherapy and skin camouflage. We investigated the efficacy and safety of …

This article is a continuation of the previous module on designing questionnaires and
clinical record form in which we have discussed some basic points about designing the …

Background In 2015, a major achievement in vitiligo research was the development of an
internationally agreed upon core outcome domain set for randomized clinical trials (RCTs) …

Around 1 in 20 people have at least one hypopigmented macule. 1 Patients may worry
about pale patches and links to other disease. Hypopigmentation can be upsetting …